Catalent

314 ‒ Rethinking nutrition science: obesity treatment, GLP-1 agonists, protein, & better research

Peter Attia MD

A company recently acquired by Novo Nordisk, which has a plant in Bloomington, Indiana, to ramp up production of GLP-1 agonists.